Vol 7, No 2 (2003)
Review paper
Published online: 2003-03-24
Microalbuminuria. Epidemiology, pathogenesis, clinical role
Bogdan Wyrzykowski
Nadciśnienie tętnicze 2003;7(2):87-98.
Vol 7, No 2 (2003)
REVIEV
Published online: 2003-03-24
Abstract
Microalbuminuria is defined as increased urinary albumin secretion which is not detectable by standard diagnostic methods. The incidence of microalbuminuria is estimated to be 20-30% in diabetes patients, 15% in hypertensive patients, and about 4-5% in patients without diabetes or hypertension. Microalbuminuria may not only reflect renal malfunction but can also be a marker of generalised angiopathy. In diabetes and hypertension microalbuminuria is a useful marker of changes in the cardiovascular system that are
already present and can indicate the risk of future cardiovascular events. Rigorous control of blood pressure in diabetes patients diminishes microalbuminuria and slows down the progression of nephropathy and the development of end-stage renal insufficiency. It is uncertain whether decreased urinary albumin secretion in hypertensive patients is associated
with similar benefits. The data available suggest that the most effective reduction in microalbuminuria is obtained from ACE inhibitors. Evidence from the NESTOR trial shows that Indapamid SR may be as effective as ACE-I in diabetes type 2 patients and hypertensive patients.
Abstract
Microalbuminuria is defined as increased urinary albumin secretion which is not detectable by standard diagnostic methods. The incidence of microalbuminuria is estimated to be 20-30% in diabetes patients, 15% in hypertensive patients, and about 4-5% in patients without diabetes or hypertension. Microalbuminuria may not only reflect renal malfunction but can also be a marker of generalised angiopathy. In diabetes and hypertension microalbuminuria is a useful marker of changes in the cardiovascular system that are
already present and can indicate the risk of future cardiovascular events. Rigorous control of blood pressure in diabetes patients diminishes microalbuminuria and slows down the progression of nephropathy and the development of end-stage renal insufficiency. It is uncertain whether decreased urinary albumin secretion in hypertensive patients is associated
with similar benefits. The data available suggest that the most effective reduction in microalbuminuria is obtained from ACE inhibitors. Evidence from the NESTOR trial shows that Indapamid SR may be as effective as ACE-I in diabetes type 2 patients and hypertensive patients.
Keywords
microalbuminuria; diabetes; hypertension; cardiovascular risk; nephropathy
Title
Microalbuminuria. Epidemiology, pathogenesis, clinical role
Journal
Arterial Hypertension
Issue
Vol 7, No 2 (2003)
Article type
Review paper
Pages
87-98
Published online
2003-03-24
Page views
924
Article views/downloads
1836
Bibliographic record
Nadciśnienie tętnicze 2003;7(2):87-98.
Keywords
microalbuminuria
diabetes
hypertension
cardiovascular risk
nephropathy
Authors
Bogdan Wyrzykowski